MCID: INP001
MIFTS: 39

Inappropriate Adh Syndrome

Categories: Endocrine diseases

Aliases & Classifications for Inappropriate Adh Syndrome

MalaCards integrated aliases for Inappropriate Adh Syndrome:

Name: Inappropriate Adh Syndrome 12 44 15 73
Syndrome of Inappropriate Secretion of Antidiuretic Hormone 12 37
Syndrome of Inappropriate Antidiuretic Hormone Secretion 12
Syndrome of Inappropriate Vasopressin Secretion 12
Syndrome of Inappropriate Secretion of Adh 12

Classifications:



External Ids:

Disease Ontology 12 DOID:3401
ICD10 33 E22.2
MeSH 44 D007177
NCIt 50 C3988
SNOMED-CT 68 389983008 55004003
KEGG 37 H01682
UMLS 73 C0021141

Summaries for Inappropriate Adh Syndrome

MalaCards based summary : Inappropriate Adh Syndrome, also known as syndrome of inappropriate secretion of antidiuretic hormone, is related to syndrome of inappropriate antidiuretic hormone and nephrogenic syndrome of inappropriate antidiuresis, and has symptoms including polyuria An important gene associated with Inappropriate Adh Syndrome is AVP (Arginine Vasopressin), and among its related pathways/superpathways are Neuroactive ligand-receptor interaction and Vasopressin-regulated water reabsorption. The drugs Tolvaptan and Empagliflozin have been mentioned in the context of this disorder. Affiliated tissues include brain, and related phenotypes are behavior/neurological and growth/size/body region

Related Diseases for Inappropriate Adh Syndrome

Diseases related to Inappropriate Adh Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 113)
# Related Disease Score Top Affiliating Genes
1 syndrome of inappropriate antidiuretic hormone 32.0 AQP2 AVP AVPR2 POMC
2 nephrogenic syndrome of inappropriate antidiuresis 31.8 AVP AVPR2
3 diabetes insipidus 28.3 AQP2 AVP AVPR2 POMC REN
4 bronchus cancer 10.6 AVP AVPR2
5 diabetes insipidus, nephrogenic, x-linked 10.6 AQP2 AVPR2
6 central nervous system germinoma 10.5 AVP POMC
7 seizures, sensorineural deafness, ataxia, mental retardation, and electrolyte imbalance 10.5 AQP2 AVP
8 tuberculous epididymitis 10.5 AVP POMC
9 peripheral vertigo 10.5 AQP2 AVP
10 central nervous system germ cell tumor 10.5 AVP POMC
11 secondary hypertrophic osteoarthropathy 10.5 AVP POMC
12 vestibular disease 10.5 AQP2 AVP
13 central nervous system organ benign neoplasm 10.5 AVP POMC
14 tuberculous empyema 10.5 AVPR2 POMC
15 cervix small cell carcinoma 10.5 AVP POMC
16 motion sickness 10.4 AQP1 AVP
17 chromophobe adenoma 10.4 AVP POMC
18 ectopic cushing syndrome 10.4 AVPR2 POMC
19 pancreas disease 10.3 AVP POMC
20 pituitary hormone deficiency, combined, 2 10.3 AVP POMC
21 spinal cord disease 10.3 AQP4 AVPR2
22 benign essential hypertension 10.3 AVP REN
23 idiopathic edema 10.3 AQP1 AQP2
24 pituitary gland disease 10.3 AVP POMC
25 intracranial hypertension, idiopathic 10.2 AQP1 AQP4
26 subependymoma 10.2 AQP1 AQP4
27 dysferlinopathy 10.2 AQP1 AQP4
28 acute adrenal insufficiency 10.2 POMC REN
29 acute hemorrhagic leukoencephalitis 10.2 AQP1 AQP4
30 hypoaldosteronism 10.2 POMC REN
31 adrenal cortical hypofunction 10.2 POMC REN
32 hyperaldosteronism, familial, type i 10.1 POMC REN
33 hepatorenal syndrome 10.1 AQP2 REN
34 temporal arteritis 10.1
35 small cell carcinoma 10.1
36 prostatitis 10.1
37 cerebritis 10.1
38 status asthmaticus 10.1
39 encephalitis 10.1
40 limbic encephalitis 10.1
41 familial glucocorticoid deficiency 10.1 POMC REN
42 ureteral disease 10.1 AQP2 REN
43 adrenal cortex disease 10.1 POMC REN
44 adrenal gland disease 10.1 POMC REN
45 apparent mineralocorticoid excess 10.1 POMC REN
46 neuromyelitis optica 10.1 AQP1 AQP4
47 intracranial hypertension 10.1 AQP1 AQP4
48 endocrine organ benign neoplasm 10.1 POMC REN
49 mineral metabolism disease 10.0 POMC REN
50 dracunculiasis 10.0 AVPR2 SNAI1

Graphical network of the top 20 diseases related to Inappropriate Adh Syndrome:



Diseases related to Inappropriate Adh Syndrome

Symptoms & Phenotypes for Inappropriate Adh Syndrome

UMLS symptoms related to Inappropriate Adh Syndrome:


polyuria

MGI Mouse Phenotypes related to Inappropriate Adh Syndrome:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 9.95 AVP AVPR2 POMC REN AQP1 AQP2
2 growth/size/body region MP:0005378 9.91 AQP1 AQP2 AQP4 AVPR2 POMC REN
3 hematopoietic system MP:0005397 9.8 AQP1 AQP2 AQP4 AVPR2 POMC REN
4 homeostasis/metabolism MP:0005376 9.8 AQP1 AQP2 AQP4 AVP AVPR2 POMC
5 mortality/aging MP:0010768 9.76 AQP1 AQP2 AQP4 AVP AVPR2 POMC
6 nervous system MP:0003631 9.43 SNAI1 AQP1 AQP4 AVP POMC REN
7 renal/urinary system MP:0005367 9.17 AQP1 AQP2 AQP4 AVP AVPR2 POMC

Drugs & Therapeutics for Inappropriate Adh Syndrome

Drugs for Inappropriate Adh Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 29)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Tolvaptan Approved Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable 150683-30-0 216237
2
Empagliflozin Approved Phase 2, Phase 3,Phase 3 864070-44-0
3 Natriuretic Agents Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable
4 Hormones Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable
5 Vasopressins Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable
6 Arginine Vasopressin Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable
7
Satavaptan Phase 3,Phase 2 185913-78-4 7029
8 Coagulants Phase 3,Phase 2,Phase 1
9 Hemostatics Phase 3,Phase 2,Phase 1
10 Deamino Arginine Vasopressin Phase 2, Phase 3
11 Hormone Antagonists Phase 3,Phase 2,Phase 1
12 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3,Phase 2,Phase 1
13 Vasoconstrictor Agents Phase 3,Phase 2,Phase 1
14 Hypoglycemic Agents Phase 2, Phase 3,Phase 3
15 Pharmaceutical Solutions Phase 2, Phase 3
16 arginine Nutraceutical Phase 3,Phase 2,Phase 1
17
Probenecid Approved, Investigational Phase 1, Phase 2 57-66-9 4911
18
Acetylcysteine Approved, Investigational Phase 1, Phase 2 616-91-1 12035
19 Renal Agents Phase 1, Phase 2
20 Respiratory System Agents Phase 1, Phase 2
21 N-monoacetylcystine Phase 1, Phase 2
22 Expectorants Phase 1, Phase 2
23 Antidotes Phase 1, Phase 2
24 Anti-Infective Agents Phase 1, Phase 2
25 Antioxidants Phase 1, Phase 2
26 Protective Agents Phase 1, Phase 2
27 Antirheumatic Agents Phase 1, Phase 2
28 Antiviral Agents Phase 1, Phase 2
29 cysteine Nutraceutical Phase 1, Phase 2

Interventional clinical trials:

(show all 22)
# Name Status NCT ID Phase Drugs
1 Urinary Aquaporine 2 in Patients With Syndrome of Inappropriate ADH-secretion Caused by Treatment With Antiepileptic Medicine Withdrawn NCT00298753 Phase 4
2 Efficacy and Safety Study of the Tolvaptan Tablets in Patients With Non-hypovolemic Non-acute Hyponatremia Unknown status NCT01507727 Phase 2, Phase 3 Tolvaptan;Placebo
3 Safety and Efficacy of SR121463B in Patients With Syndrome of Inappropriate Antidiuretic Hormone Secretion Completed NCT00264914 Phase 3 SR121463B
4 Efficacy and Safety of SR121463B in Patients With Syndrome of Inappropriate Antidiuretic Hormone Secretion Completed NCT00264927 Phase 3 SR121463B
5 Effects of Empagliflozin an SGLT2-Inhibitor on Healthy Volunteers With Induced Hypotonic Hyponatremia - the DIVE Study Completed NCT02729766 Phase 2, Phase 3 Empagliflozin 25mg Tbl;Placebo P-Tablet
6 "SALT-2 Trial" Study of Ascending Levels of Tolvaptan in Hyponatremia Completed NCT00201994 Phase 3 Tolvaptan
7 “SALT Trial” Study of Ascending Levels of Tolvaptan in Hyponatremia Completed NCT00072683 Phase 3 tolvaptan
8 A Multicenter Trial to Investigate the Efficacy and Safety of Tolvaptan in Patients With Hyponatremia in SIADH Recruiting NCT03048747 Phase 3 Tolvaptan Oral Tablet
9 Effects of the SGLT2-inhibitor Empagliflozin on Patients With Chronic SIADH - the SANDx Study Recruiting NCT03202667 Phase 2, Phase 3 Empagliflozin 25mg;Placebo
10 Effects of the SGLT2-inhibitor Empagliflozin on Patients With SIADH - the SAND Study Enrolling by invitation NCT02874807 Phase 2, Phase 3 Empagliflozin
11 A Phase III Study Evaluating the Efficacy and Safety of Satavaptan Versus Placebo in Patients With Dilutional Hyponatremia Terminated NCT00728091 Phase 3 Satavaptan;placebo
12 Effects of Tolvaptan vs Fluid Restriction in Hospitalized Subjects With Dilutional Hyponatremia Terminated NCT01227512 Phase 3 tolvaptan
13 Efficacy of SR121463B in Patients With Syndrome of Inappropriate Antidiuretic Hormone Secretion Completed NCT00032734 Phase 2 satavaptan (SR121463B)
14 A PK Study of 3 Dosages of Tolvaptan in Patients With Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH) Completed NCT02009878 Phase 1, Phase 2 tolvaptan
15 Overcoming Membrane Transporters to Improve CNS Drug Delivery - Improving Brain Antioxidants After Traumatic Brain Injury Completed NCT01322009 Phase 1, Phase 2 Probenecid and N-acetyl cysteine;Placebo
16 Subclassification of the Syndrome of Inappropriate ADH Secretion Completed NCT01341665
17 An Observational Study on Real-world Use and Outcomes of Patients Treated With Tolvaptan for Hyponatraemia Due to SIADH Completed NCT02545101
18 An Observational Study to Describe the Adherence to the SEOM Algorithm for the Treatment of Hyponatraemia in Spain Completed NCT02548845
19 An Observational Study Measuring Outcomes in Cancer Patients Treated for Moderate to Severe Hyponatremia in Italy Completed NCT02573077
20 Hyponatremia Registry for Patients With Euvolemic and Hypervolemic Hyponatremia Completed NCT01240668
21 Evaluation of Plasma Volume Using Ultrasound in Disorders of Fluid With Sodium Active, not recruiting NCT01547650
22 Fractional Urate Excretion in Nonedematous Hyponatremia Withdrawn NCT01425125 Not Applicable Tolvaptan in euvolemic hyponatremia

Search NIH Clinical Center for Inappropriate Adh Syndrome

Cochrane evidence based reviews: inappropriate adh syndrome

Genetic Tests for Inappropriate Adh Syndrome

Anatomical Context for Inappropriate Adh Syndrome

MalaCards organs/tissues related to Inappropriate Adh Syndrome:

41
Brain

Publications for Inappropriate Adh Syndrome

Articles related to Inappropriate Adh Syndrome:

# Title Authors Year
1
Case of inappropriate ADH syndrome: hyponatremia due to polyethylene glycol bowel preparation. ( 25232272 )
2014
2
Hyponatraemia and the inappropriate ADH syndrome in pneumonia. ( 1283678 )
1992
3
How to recognize and treat the inappropriate ADH syndrome. ( 1214567 )
1975
4
Urinary antidiuretic hormone in polyuric disorders and in inappropriate ADH syndrome. ( 4343077 )
1972
5
Correction of an inappropriate ADH syndrome by tumor resection. ( 5636059 )
1968
6
Antidiuretic principle in malignant tumor extracts from patients with inappropriate ADH syndrome. ( 5688815 )
1968

Variations for Inappropriate Adh Syndrome

Expression for Inappropriate Adh Syndrome

Search GEO for disease gene expression data for Inappropriate Adh Syndrome.

Pathways for Inappropriate Adh Syndrome

Pathways related to Inappropriate Adh Syndrome according to KEGG:

37
# Name Kegg Source Accession
1 Neuroactive ligand-receptor interaction hsa04080
2 Vasopressin-regulated water reabsorption hsa04962

Pathways related to Inappropriate Adh Syndrome according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.78 AQP1 AQP2 AQP4 AVP AVPR2
2
Show member pathways
11.77 AQP1 AQP2 AQP4 AVP AVPR2
3 11.5 AVP AVPR2 POMC
4 11.22 AQP1 AQP4
5 11.13 AQP1 REN
6 10.57 AQP2 AQP4 AVP AVPR2

GO Terms for Inappropriate Adh Syndrome

Cellular components related to Inappropriate Adh Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 clathrin-coated vesicle membrane GO:0030665 8.96 AVP AVPR2
2 basolateral plasma membrane GO:0016323 8.8 AQP1 AQP2 AQP4

Biological processes related to Inappropriate Adh Syndrome according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 ion transmembrane transport GO:0034220 9.67 AQP1 AQP2 AQP4
2 negative regulation of cysteine-type endopeptidase activity involved in apoptotic process GO:0043154 9.54 AQP1 AVP
3 regulation of blood pressure GO:0008217 9.52 POMC REN
4 generation of precursor metabolites and energy GO:0006091 9.51 AVP POMC
5 excretion GO:0007588 9.48 AQP2 AVPR2
6 positive regulation of vasoconstriction GO:0045907 9.46 AVP AVPR2
7 cellular response to copper ion GO:0071280 9.43 AQP1 AQP2
8 glycerol transport GO:0015793 9.4 AQP1 AQP2
9 positive regulation of systemic arterial blood pressure GO:0003084 9.37 AVP AVPR2
10 multicellular organismal water homeostasis GO:0050891 9.33 AQP1 AQP4 AVP
11 cellular response to mercury ion GO:0071288 9.32 AQP1 AQP2
12 renal water transport GO:0003097 9.26 AQP1 AQP2
13 water transport GO:0006833 9.26 AQP1 AQP2 AQP4 AVP
14 renal water homeostasis GO:0003091 9.02 AQP1 AQP2 AQP4 AVP AVPR2

Molecular functions related to Inappropriate Adh Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 channel activity GO:0015267 9.33 AQP1 AQP2 AQP4
2 neuropeptide hormone activity GO:0005184 9.32 AVP POMC
3 glycerol transmembrane transporter activity GO:0015168 9.26 AQP1 AQP2
4 water channel activity GO:0015250 9.13 AQP1 AQP2 AQP4
5 water transmembrane transporter activity GO:0005372 8.8 AQP1 AQP2 AQP4

Sources for Inappropriate Adh Syndrome

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....